Ask The Board

  1. What Big Biopharma Companies Do You Find Most Exciting And Why?

    A: I AM IMPRESSED BY BRISTOL-MEYERS SQUIBB (BMS) AND J&J. Ten years ago you wouldn’t have given BMS much of a chance after the channel-stuffing scandal. But today BMS finds itself as a very successful specialty biopharma company.

  2. What Simple Changes To Biopharma Manufacturing Could Be Quickly Implemented To Lower Drug Prices?

    A: UNFORTUNATELY, NO CHANGE in the highly regulated bioprocess industry is “simple;” and it requires appropriate risk assessment.

  3. What Do You Say To Those Who Are Looking At A Job Description/Career That Requires Prior Experience?

    A: IT CAN FEEL LIKE A CATCH-22 when a role requires specific experience to be considered a candidate, yet you can’t get experience unless you are in that type of role! One solution to this dilemma is gaining the experience you need outside of your company. Associations offer the perfect opportunity to do just this. Consider what research and volunteer opportunities your industry’s association has that are aligned to your target area.

  4. List Some Key Characteristics You Look For When Recruiting Engineers And How To Tease These Out.

    ASIDE FROM ENGINEERING ABILITY, I try to assess their skills related to explaining their subject, working in a team, and negotiating corporate bureaucracy.

  5. What Are Some Fundamental Challenges Facing Biopharma Manufacturers?

    A: AT THE GLOBAL PHARMACEUTICAL MANUFACTURING LEADERSHIP FORUM IN FRANKFURT, GERMANY, a list of current biopharma industry construction projects was presented.

  6. What Clinical Trial Requirements Or Practices Could Be Revised To Provide Quick Cost Reductions And Perhaps Result In Lower Drug Prices?

    OVERALL, I DON’T SEE REGULATORY ISSUES DRIVING DRUG PRICES, unless you are talking about fundamentally decreasing the overall cost of drug development. Drug pricing is more connected with outcomes, health economics, value-based reimbursement, and contracting power.

  7. What Simple Solutions Can Biopharma Executives Implement To Positively Impact Public Perception?

    A: IT WILL TAKE A SUSTAINED EFFORT, NOT “SILVER BULLETS,” to turn the public perception tide. Collectively, industry professionals – and leaders in particular — need to be passionate, yet thoughtful advocates for the science that motivates us every day.

  8. What Mechanisms Can Be Used To Encourage U.S. Companies To Bring Back Their Overseas “Stranded Capital”?


  9. Knowing What You Know Now, What Would You Do Differently In Founding A Biopharma Company?

    A: THE MOST IMPORTANT LESSON I’VE LEARNED CAME FROM MY CURRENT COMPANY: Do not develop innovative products for devastating unmet medical needs whose care is dominated by public health officials and advocacy groups.

  10. Do You Think The FDA Draft Guidance On Metrics Takes The Industry In The Right Direction?

    A: THE INTENT OF THE COLLECTION OF INDUSTRY METRICS IS IN THE RIGHT DIRECTION. To date, the information the FDA gathers is limited to compliance data, which provides only a snapshot of the compliance level of a site and some indication of quality based on a limited set of surrogate measures.